SFI1 Antibody

What is the SFI1 protein and what cellular structures is it associated with?

SFI1 (Protein SFI1 Homolog) is a bona fide centriolar protein that specifically localizes to the very distal end of the centriole where it associates with a pool of distal centrin. Research has demonstrated that SFI1 is recruited early during procentriole assembly and forms a critical SFI1/centrin complex essential for maintaining correct centriolar architecture and function as a basal body . The protein's presence at centrosomes persists throughout the cell cycle, making it an important marker for studying centrosome biology . Using super-resolution ultrastructure expansion microscopy (U-ExM), researchers have visualized SFI1 as a distinct dot at the very distal tip of mature centrioles in both RPE-1 and U2OS cell lines .

What are the key specifications of commercially available SFI1 antibodies?

Standard research-grade SFI1 antibodies typically include the following specifications:

These specifications provide the foundation for experimental design when using SFI1 antibodies in research contexts .

How can I verify the specificity of my SFI1 antibody?

Verification of SFI1 antibody specificity is essential for reliable experimental outcomes. A robust approach involves performing immunofluorescence analysis on cells depleted of SFI1 through siRNA treatment. In validated studies, researchers demonstrated that the distinct distal dot corresponding to SFI1 disappeared in SFI1-depleted RPE-1 cells, confirming signal specificity . This verification was conducted with both custom-produced antibodies (against residues 1021 to 1240) and commercially available SFI1 antibodies (such as 13550-1-AP from Proteintech Europe), with both showing similar localization patterns at the distal extremity that diminished following siRNA depletion . Additionally, Western blot analysis showing a band at the expected molecular weight (observed at 148 kDa) provides further confirmation of specificity .

What techniques can be used to visualize SFI1 localization at centrioles with high precision?

Super-resolution ultrastructure expansion microscopy (U-ExM) has proven particularly effective for precise localization of SFI1 at centrioles. Using this technique, researchers have demonstrated that SFI1 appears as a distinct dot at the very distal tip of mature centrioles in both RPE-1 and U2OS cells . This approach allows visualization of SFI1's relationship with other centriolar components with nanometer-scale resolution. The methodology involves:

• Sample preparation with standard immunofluorescence protocols

• Tissue expansion using U-ExM methodology

• Staining with validated SFI1 antibodies (such as custom antibodies against the C-terminus fragment encompassing residues 1021 to 1240)

• Co-staining with markers such as γ-tubulin or centrin (using the 20H5 monoclonal antibody)

• Imaging using super-resolution microscopy techniques

This approach reveals not only the primary distal localization of SFI1 but can also detect fainter signals, such as the dotty proximal signal that might reflect additional SFI1 locations .

How does SFI1 depletion affect centrin localization and what does this reveal about their functional relationship?

SFI1 depletion studies demonstrate a direct functional relationship between SFI1 and centrin positioning at centrioles. When SFI1 is depleted through siRNA treatment, centrin signal is significantly reduced, often remaining present at only one centriole, while other markers like CP110 remain unchanged . Expansion microscopy has revealed that 97% of SFI1-depleted cells lose the distal dot of SFI1, and correspondingly, 97% of centrioles lose centrin specifically at their distal end while maintaining the centrin pool at the central core region . This localization dependency suggests that SFI1 is required for recruiting or maintaining the distal pool of centrin, forming a SFI1/centrin complex that is essential for proper centriolar architecture. The methodological approach to investigating this relationship involves:

• siRNA-mediated depletion of SFI1

• Immunofluorescence analysis using both conventional and super-resolution microscopy

• Quantification of centrin signal intensity and localization patterns

• Comparative analysis with control cells to identify specific effects of SFI1 depletion

What is the impact of SFI1 depletion on centriole biogenesis and architecture?

Despite being critical for SPB duplication in yeast, SFI1 depletion does not impair centriole duplication in human cells, revealing an interesting evolutionary divergence in SFI1 function. When studying centriole duplication in SFI1-depleted U2OS cells using tubulin staining via U-ExM, researchers found that procentrioles form normally, with no significant difference in the percentage of cells harboring procentrioles between control (42% ±6) and SFI1-depleted cells (40% ±4) . Furthermore, the cartwheel proteins HsSAS-6 and STIL are still recruited to growing procentrioles in SFI1-depleted cells, contradicting earlier findings that suggested SFI1-depleted HeLa cells failed to recruit these proteins .

What are the optimal conditions for using SFI1 antibodies in Western blotting experiments?

When designing Western blotting experiments with SFI1 antibodies, researchers should consider the following optimized conditions:

• Dilution range: 1/500 to 1/2000 of the antibody solution (typically at 1 mg/ml concentration)

• Buffer composition: PBS, pH 7.3, containing 0.02% sodium azide, 50% glycerol

• Expected molecular weight: Look for a band at approximately 148 kDa (observed) or 117-147 kDa (calculated)

• Sample preparation: Standard protein extraction protocols are suitable, with care taken to prevent protein degradation

• Controls: Include positive controls (tissues/cells known to express SFI1) and negative controls (SFI1-depleted samples)

The optimal dilution should be determined empirically for each specific application and sample type, as antibody performance can vary depending on the experimental conditions and the specific lot of antibody .

How can I design experiments to study the functional relationship between SFI1 and centrin?

To investigate the functional relationship between SFI1 and centrin, a comprehensive experimental design might include:

• Co-localization studies using dual immunofluorescence with SFI1 and centrin antibodies (such as the centrin 20H5 monoclonal antibody that recognizes human centrin 2 and centrin 3)

• Super-resolution microscopy (such as U-ExM) to precisely map the spatial relationship between these proteins at centrioles

• RNA interference approaches targeting SFI1 (using validated siRNA sequences) to assess the impact on centrin localization and centriole morphology

• Functional assays to evaluate the consequences of disrupting the SFI1/centrin complex, such as:

  • Ciliogenesis assays

  • Cell cycle progression analysis

  • Centriole integrity assessments using roundness index measurements

• Biochemical interaction studies such as co-immunoprecipitation to confirm direct interaction between SFI1 and centrin

This multi-faceted approach allows researchers to establish both the physical and functional relationships between these proteins in maintaining centriolar architecture and function.

What controls are essential when studying SFI1 localization and function via antibody staining?

When designing experiments to study SFI1 localization and function using antibody-based detection methods, the following controls are critical:

• SFI1 knockdown controls: Include samples where SFI1 has been depleted via siRNA treatment to confirm antibody specificity

• Secondary antibody-only controls: To assess background fluorescence

• Multiple antibody validation: Verify localization patterns using different antibodies targeting distinct epitopes of SFI1 (such as comparing custom-raised antibodies with commercial options)

• Co-staining with established centriolar markers: Such as γ-tubulin or centrin to confirm centriolar localization

• Quantitative assessment: Include metrics such as signal intensity measurements and localization patterns in a statistically significant number of cells

• Rescue experiments: Reintroduction of siRNA-resistant SFI1 to confirm phenotype specificity

In published studies, researchers have demonstrated that both custom antibodies (against residues 1021-1240) and commercial antibodies (such as 13550-1-AP from Proteintech Europe) show the same distal localization pattern that diminishes upon siRNA depletion, providing robust validation of antibody specificity .

How can SFI1 antibodies be used to investigate the role of SFI1 in ciliogenesis?

SFI1/centrin complexes have been shown to be essential for ciliogenesis, making SFI1 antibodies valuable tools for studying this process. A methodological approach to investigating SFI1's role in ciliogenesis might include:

• Immunofluorescence analysis of SFI1 localization during cilia formation using validated antibodies

• Depletion studies combining siRNA against SFI1 with ciliogenesis assays (such as serum starvation protocols to induce cilia formation)

• Quantification of cilia formation efficiency, length, and morphology in control versus SFI1-depleted cells

• Super-resolution microscopy to examine the precise localization of SFI1 at the basal body during different stages of ciliogenesis

• Rescue experiments to determine which domains of SFI1 are critical for its function in ciliogenesis

This approach can reveal how SFI1's role at the distal end of centrioles contributes to the centriole's function as a basal body during cilia formation, a critical process in numerous developmental and physiological contexts.

What methodologies are recommended for investigating potential binding partners of SFI1 besides centrin?

To identify and characterize potential binding partners of SFI1 beyond the established interaction with centrin, researchers might employ the following methodological approaches:

• Immunoprecipitation using validated SFI1 antibodies followed by mass spectrometry analysis to identify co-precipitating proteins

• Proximity labeling approaches such as BioID or APEX to identify proteins in close proximity to SFI1 in living cells

• Yeast two-hybrid screening using full-length SFI1 or specific domains as bait

• Co-localization studies combining SFI1 antibodies with antibodies against candidate interacting proteins

• FRET (Förster Resonance Energy Transfer) or BiFC (Bimolecular Fluorescence Complementation) assays to confirm direct interactions in cellular contexts

• Domain mapping experiments to identify which regions of SFI1 are required for specific protein-protein interactions

These approaches can expand our understanding of SFI1's functional network beyond its established role with centrin, potentially revealing new insights into centriole assembly and function.

How do afucosylated antibodies compare to standard antibodies for specialized research applications?

While not directly related to SFI1 antibodies, understanding the properties of afucosylated antibodies can be valuable for researchers working with specialized antibody applications:

Afucosylated antibodies have significantly enhanced binding to FcγRIIIa receptors compared to their fucosylated counterparts, leading to improved NK cell activation and effector functions like antibody-dependent cellular cytotoxicity (ADCC) . These antibodies can induce effector functions at lower antigen densities, which is particularly advantageous when studying proteins with sparse expression .

For research applications requiring enhanced effector functions, such as studying clearance of infected cells, afucosylated antibodies offer significant advantages:

• They enhance NK cell activation and degranulation even at low antigen density

• They induce stronger intracellular signaling pathways in NK cells

• They enable sequential engagement of multiple target cells, resulting in serial killing

• Their production involves glyco-engineering techniques that can be applied to various antibodies without altering antigen binding properties

While current SFI1 antibodies are typically of standard glycosylation patterns, the principles of afucosylation could potentially be applied to create SFI1 antibodies with enhanced functional properties for specialized applications.

What are common challenges when using SFI1 antibodies and how can they be addressed?

Researchers working with SFI1 antibodies may encounter several challenges that can be addressed with appropriate troubleshooting strategies:

• Low signal intensity in immunofluorescence:

  • Optimize antibody concentration (try a range from 1/500 to 1/2000)

  • Extend primary antibody incubation time or temperature

  • Enhance antigen retrieval methods

  • Use signal amplification systems

• Non-specific background staining:

  • Increase blocking time or concentration

  • Use alternative blocking agents (BSA, normal serum, commercial blockers)

  • Optimize antibody dilution

  • Pre-absorb antibody with non-specific proteins

• Inconsistent detection of the distal SFI1 dot:

  • Ensure proper cell fixation (paraformaldehyde fixation is typically effective)

  • Optimize permeabilization conditions

  • Consider super-resolution techniques like U-ExM for better visualization

  • Use co-staining with centrin as a reference marker

• Variable results between experiments:

  • Standardize cell culture conditions

  • Control for cell cycle stage (as centrosome composition varies throughout the cell cycle)

  • Aliquot antibodies to avoid repeated freeze/thaw cycles

  • Include quantitative controls in each experiment

How can I reconcile contradictory findings regarding SFI1's role in centriole duplication?

The literature contains some contradictory findings regarding SFI1's role in centriole duplication. While SFI1 is essential for SPB duplication in yeast, studies in human cells have yielded conflicting results. Some research suggests SFI1 depletion impacts centriole duplication, while other studies find no effect on duplication but instead observe impacts on centriole architecture .

To reconcile these contradictions, consider the following methodological approaches:

• Cell type-specific effects: Compare SFI1 depletion in different cell lines (e.g., U2OS, RPE-1, HeLa) using identical methods

• Depletion efficiency assessment: Quantify SFI1 depletion levels using both immunofluorescence and Western blotting

• Timing analysis: Examine the effects of SFI1 depletion at different cell cycle stages

• Marker selection: Use multiple independent markers for centriole duplication beyond centrin (e.g., tubulin staining, HsSAS-6, STIL)

• High-resolution imaging: Employ super-resolution techniques like U-ExM to directly visualize procentriole formation

• Rescue experiments: Perform complementation with siRNA-resistant SFI1 constructs

Recent research using these approaches demonstrated that in U2OS cells, SFI1 depletion does not prevent procentriole formation or the recruitment of cartwheel proteins (HsSAS-6 and STIL), suggesting that SFI1's primary role in human cells may be in maintaining centriolar architecture rather than in duplication per se .

What considerations are important when interpreting SFI1 localization data from different imaging techniques?

When interpreting SFI1 localization data, researchers should consider several factors that can affect the observed results across different imaging techniques:

• Resolution limitations: Standard confocal microscopy may not resolve the precise localization of SFI1 at the distal end of centrioles, potentially leading to misinterpretation of its distribution

• Antibody accessibility: The compact structure of centrioles may limit antibody penetration, particularly in standard immunofluorescence protocols

• Epitope masking: Protein-protein interactions or conformational changes may mask the epitope recognized by the antibody in certain cellular contexts

• Fixation artifacts: Different fixation methods can affect protein localization patterns and antibody accessibility

• Cell cycle variations: SFI1 localization patterns may vary throughout the cell cycle, requiring careful staging of cells for consistent results

To address these considerations, researchers should:

• Compare results across multiple imaging techniques (standard immunofluorescence, super-resolution methods like U-ExM)

• Use multiple antibodies targeting different epitopes of SFI1

• Include appropriate controls (SFI1-depleted cells, cell cycle markers)

• Quantify localization patterns across statistically significant numbers of cells

• Consider three-dimensional analysis to fully capture SFI1's distribution at centrioles